Share Price and Basic Stock Data
Last Updated: March 8, 2025, 1:29 pm
| PEG Ratio | 2.21 |
|---|
Competitors of Lyka Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MPS Pharmaa Ltd | 6.71 Cr. | 3.51 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 53.1 Cr. | 71.5 | 94.9/32.1 | 18.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.0/8.74 | 38.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Godavari Drugs Ltd | 70.4 Cr. | 93.5 | 155/79.0 | 11.4 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
| Industry Average | 17,255.37 Cr | 1,081.84 | 42.42 | 185.80 | 0.37% | 16.00% | 16.32% | 6.27 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.57 | 35.19 | 27.49 | 25.53 | 17.82 | 22.24 | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 |
| Expenses | 22.55 | 22.59 | 21.18 | 20.50 | 15.61 | 18.94 | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 |
| Operating Profit | 13.02 | 12.60 | 6.31 | 5.03 | 2.21 | 3.30 | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 |
| OPM % | 36.60% | 35.81% | 22.95% | 19.70% | 12.40% | 14.84% | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% |
| Other Income | 0.58 | -2.27 | 0.95 | 0.98 | -5.95 | 0.02 | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 |
| Interest | 4.64 | 2.99 | 2.91 | 3.03 | 3.08 | 2.85 | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 |
| Depreciation | 2.24 | 9.46 | 3.59 | 3.62 | 3.47 | 3.47 | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 |
| Profit before tax | 6.72 | -2.12 | 0.76 | -0.64 | -10.29 | -3.00 | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 |
| Tax % | 6.55% | 607.08% | 6.58% | -46.88% | 2.24% | 0.00% | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% |
| Net Profit | 6.09 | -15.07 | 0.60 | -0.38 | -10.42 | -3.01 | -1.85 | -0.49 | 1.78 | -2.13 | 1.44 | 2.10 | 2.71 |
| EPS in Rs | 2.12 | -5.25 | 0.21 | -0.13 | -3.63 | -0.98 | -0.56 | -0.15 | 0.54 | -0.64 | 0.40 | 0.59 | 0.76 |
Last Updated: February 28, 2025, 6:41 pm
Below is a detailed analysis of the quarterly data for Lyka Labs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹33.80 Cr.. The value appears to be declining and may need further review. It has decreased from 41.16 Cr. (Sep 2024) to ₹33.80 Cr., marking a decrease of 7.36 Cr..
- For Expenses, as of Dec 2024, the value is ₹28.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.21 Cr. (Sep 2024) to ₹28.61 Cr., marking a decrease of 7.60 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹5.19 Cr.. The value appears strong and on an upward trend. It has increased from 4.95 Cr. (Sep 2024) to ₹5.19 Cr., marking an increase of ₹0.24 Cr..
- For OPM %, as of Dec 2024, the value is 15.36%. The value appears strong and on an upward trend. It has increased from 12.03% (Sep 2024) to 15.36%, marking an increase of 3.33%.
- For Other Income, as of Dec 2024, the value is ₹0.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Sep 2024) to ₹0.83 Cr., marking an increase of ₹0.80 Cr..
- For Interest, as of Dec 2024, the value is ₹0.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.54 Cr. (Sep 2024) to ₹0.61 Cr., marking an increase of ₹0.07 Cr..
- For Depreciation, as of Dec 2024, the value is ₹1.83 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.76 Cr. (Sep 2024) to ₹1.83 Cr., marking an increase of ₹0.07 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹3.58 Cr.. The value appears strong and on an upward trend. It has increased from 2.68 Cr. (Sep 2024) to ₹3.58 Cr., marking an increase of ₹0.90 Cr..
- For Tax %, as of Dec 2024, the value is 24.30%. The value appears to be improving (decreasing) as expected. It has decreased from 28.36% (Sep 2024) to 24.30%, marking a decrease of 4.06%.
- For Net Profit, as of Dec 2024, the value is ₹2.71 Cr.. The value appears strong and on an upward trend. It has increased from 2.10 Cr. (Sep 2024) to ₹2.71 Cr., marking an increase of ₹0.61 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.76. The value appears strong and on an upward trend. It has increased from ₹0.59 (Sep 2024) to 0.76, marking an increase of ₹0.17.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 3:37 pm
| Metric | Mar 2013 | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 127 | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 133 |
| Expenses | 99 | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 117 |
| Operating Profit | 28 | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 16 |
| OPM % | 22% | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 12% |
| Other Income | 3 | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 |
| Interest | 19 | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 3 |
| Depreciation | 12 | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 8 |
| Profit before tax | 0 | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 6 |
| Tax % | 0% | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | |
| Net Profit | -1 | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 4 |
| EPS in Rs | -0.33 | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 1.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -171.43% | 68.42% | -950.00% | 84.13% | 480.00% | -134.21% | 76.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | 239.85% | -1018.42% | 1034.13% | 395.87% | -614.21% | 211.13% |
Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 14, 2024, 3:14 pm
| Month | Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
| Reserves | 44 | 30 | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 63 |
| Borrowings | 127 | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 35 |
| Other Liabilities | 96 | 113 | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 34 |
| Total Liabilities | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 168 |
| Fixed Assets | 93 | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 58 |
| CWIP | 47 | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 28 |
| Investments | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 143 | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 83 |
| Total Assets | 289 | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 168 |
Below is a detailed analysis of the balance sheet data for Lyka Labs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹36.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹33.00 Cr. (Mar 2024) to ₹36.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹63.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹35.00 Cr. (Mar 2024) to ₹63.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹59.00 Cr. (Mar 2024) to ₹35.00 Cr., marking a decrease of 24.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹30.00 Cr. (Mar 2024) to ₹34.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹168.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹157.00 Cr. (Mar 2024) to ₹168.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹58.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹58.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹28.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹23.00 Cr. (Mar 2024) to ₹28.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹83.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹76.00 Cr. (Mar 2024) to ₹83.00 Cr., marking an increase of 7.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹168.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹157.00 Cr. (Mar 2024) to ₹168.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (₹63.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Jun 2014n n 15m | Jun 2015 | Mar 2013 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.00 | -109.00 | -99.00 | 20.00 | -103.00 | -117.00 | -98.00 | -145.00 | -143.00 | -29.00 | -58.00 | -43.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211 | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 |
| Inventory Days | 99 | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 |
| Days Payable | 236 | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 |
| Cash Conversion Cycle | 73 | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 |
| Working Capital Days | 96 | -106 | -88 | -75 | -191 | -456 | -181 | -156 | -71 | 6 | 34 | 71 |
| ROCE % | 10% | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% |
This stock is not held by any mutual fund
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.79 | -4.63 | 13.57 | -4.07 | -21.29 |
| Diluted EPS (Rs.) | -0.79 | -4.63 | 13.57 | -4.07 | -21.29 |
| Cash EPS (Rs.) | 3.08 | 0.32 | 19.45 | -0.61 | -19.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.63 | 14.88 | 4.70 | -8.75 | -5.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.63 | 14.88 | 4.70 | -8.75 | -5.27 |
| Revenue From Operations / Share (Rs.) | 33.60 | 30.33 | 67.65 | 30.06 | 21.43 |
| PBDIT / Share (Rs.) | 5.19 | 6.59 | 35.99 | 7.41 | -0.20 |
| PBIT / Share (Rs.) | 1.32 | 1.99 | 29.94 | 4.50 | -2.99 |
| PBT / Share (Rs.) | -0.28 | -4.29 | 20.65 | -4.93 | -21.57 |
| Net Profit / Share (Rs.) | -0.79 | -4.29 | 13.40 | -3.52 | -21.83 |
| NP After MI And SOA / Share (Rs.) | -0.75 | -4.30 | 13.59 | -4.03 | -21.10 |
| PBDIT Margin (%) | 15.44 | 21.74 | 53.19 | 24.63 | -0.94 |
| PBIT Margin (%) | 3.92 | 6.54 | 44.25 | 14.98 | -13.96 |
| PBT Margin (%) | -0.83 | -14.15 | 30.52 | -16.39 | -100.63 |
| Net Profit Margin (%) | -2.35 | -14.13 | 19.80 | -11.69 | -101.84 |
| NP After MI And SOA Margin (%) | -2.23 | -14.19 | 20.09 | -13.39 | -98.45 |
| Return on Networth / Equity (%) | -3.65 | -29.07 | 292.38 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 3.66 | 5.12 | 99.57 | 9.17 | -6.41 |
| Return On Assets (%) | -1.58 | -8.71 | 21.01 | -6.08 | -30.24 |
| Long Term Debt / Equity (X) | 0.62 | 1.38 | 4.63 | -5.84 | -8.75 |
| Total Debt / Equity (X) | 0.84 | 1.55 | 9.66 | -6.24 | -9.75 |
| Asset Turnover Ratio (%) | 0.72 | 0.44 | 0.82 | 0.30 | 0.18 |
| Current Ratio (X) | 1.35 | 1.36 | 0.52 | 0.59 | 0.54 |
| Quick Ratio (X) | 1.09 | 1.14 | 0.44 | 0.50 | 0.43 |
| Inventory Turnover Ratio (X) | 3.89 | 3.05 | 4.31 | 2.23 | 2.12 |
| Interest Coverage Ratio (X) | 3.51 | 1.71 | 5.13 | 0.81 | -0.02 |
| Interest Coverage Ratio (Post Tax) (X) | 0.54 | 0.51 | 3.23 | 0.65 | -0.46 |
| Enterprise Value (Cr.) | 402.09 | 381.55 | 501.74 | 229.87 | 166.02 |
| EV / Net Operating Revenue (X) | 3.62 | 4.10 | 2.59 | 2.67 | 2.70 |
| EV / EBITDA (X) | 23.42 | 18.85 | 4.86 | 10.82 | -286.39 |
| MarketCap / Net Operating Revenue (X) | 3.15 | 3.45 | 2.00 | 0.86 | 0.59 |
| Price / BV (X) | 5.14 | 7.07 | 29.17 | -2.89 | -2.55 |
| Price / Net Operating Revenue (X) | 3.15 | 3.45 | 2.00 | 0.86 | 0.59 |
| EarningsYield | -0.01 | -0.04 | 0.10 | -0.15 | -1.65 |
After reviewing the key financial ratios for Lyka Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 5. It has increased from -4.63 (Mar 23) to -0.79, marking an increase of 3.84.
- For Diluted EPS (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 5. It has increased from -4.63 (Mar 23) to -0.79, marking an increase of 3.84.
- For Cash EPS (Rs.), as of Mar 24, the value is 3.08. This value is within the healthy range. It has increased from 0.32 (Mar 23) to 3.08, marking an increase of 2.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 20.63. It has increased from 14.88 (Mar 23) to 20.63, marking an increase of 5.75.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 20.63. It has increased from 14.88 (Mar 23) to 20.63, marking an increase of 5.75.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 33.60. It has increased from 30.33 (Mar 23) to 33.60, marking an increase of 3.27.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 5.19. This value is within the healthy range. It has decreased from 6.59 (Mar 23) to 5.19, marking a decrease of 1.40.
- For PBIT / Share (Rs.), as of Mar 24, the value is 1.32. This value is within the healthy range. It has decreased from 1.99 (Mar 23) to 1.32, marking a decrease of 0.67.
- For PBT / Share (Rs.), as of Mar 24, the value is -0.28. This value is below the healthy minimum of 0. It has increased from -4.29 (Mar 23) to -0.28, marking an increase of 4.01.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 2. It has increased from -4.29 (Mar 23) to -0.79, marking an increase of 3.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -0.75. This value is below the healthy minimum of 2. It has increased from -4.30 (Mar 23) to -0.75, marking an increase of 3.55.
- For PBDIT Margin (%), as of Mar 24, the value is 15.44. This value is within the healthy range. It has decreased from 21.74 (Mar 23) to 15.44, marking a decrease of 6.30.
- For PBIT Margin (%), as of Mar 24, the value is 3.92. This value is below the healthy minimum of 10. It has decreased from 6.54 (Mar 23) to 3.92, marking a decrease of 2.62.
- For PBT Margin (%), as of Mar 24, the value is -0.83. This value is below the healthy minimum of 10. It has increased from -14.15 (Mar 23) to -0.83, marking an increase of 13.32.
- For Net Profit Margin (%), as of Mar 24, the value is -2.35. This value is below the healthy minimum of 5. It has increased from -14.13 (Mar 23) to -2.35, marking an increase of 11.78.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.23. This value is below the healthy minimum of 8. It has increased from -14.19 (Mar 23) to -2.23, marking an increase of 11.96.
- For Return on Networth / Equity (%), as of Mar 24, the value is -3.65. This value is below the healthy minimum of 15. It has increased from -29.07 (Mar 23) to -3.65, marking an increase of 25.42.
- For Return on Capital Employeed (%), as of Mar 24, the value is 3.66. This value is below the healthy minimum of 10. It has decreased from 5.12 (Mar 23) to 3.66, marking a decrease of 1.46.
- For Return On Assets (%), as of Mar 24, the value is -1.58. This value is below the healthy minimum of 5. It has increased from -8.71 (Mar 23) to -1.58, marking an increase of 7.13.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.62. This value is within the healthy range. It has decreased from 1.38 (Mar 23) to 0.62, marking a decrease of 0.76.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.84. This value is within the healthy range. It has decreased from 1.55 (Mar 23) to 0.84, marking a decrease of 0.71.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.72. It has increased from 0.44 (Mar 23) to 0.72, marking an increase of 0.28.
- For Current Ratio (X), as of Mar 24, the value is 1.35. This value is below the healthy minimum of 1.5. It has decreased from 1.36 (Mar 23) to 1.35, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 24, the value is 1.09. This value is within the healthy range. It has decreased from 1.14 (Mar 23) to 1.09, marking a decrease of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.89. This value is below the healthy minimum of 4. It has increased from 3.05 (Mar 23) to 3.89, marking an increase of 0.84.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 3.51. This value is within the healthy range. It has increased from 1.71 (Mar 23) to 3.51, marking an increase of 1.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.54. This value is below the healthy minimum of 3. It has increased from 0.51 (Mar 23) to 0.54, marking an increase of 0.03.
- For Enterprise Value (Cr.), as of Mar 24, the value is 402.09. It has increased from 381.55 (Mar 23) to 402.09, marking an increase of 20.54.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.62. This value exceeds the healthy maximum of 3. It has decreased from 4.10 (Mar 23) to 3.62, marking a decrease of 0.48.
- For EV / EBITDA (X), as of Mar 24, the value is 23.42. This value exceeds the healthy maximum of 15. It has increased from 18.85 (Mar 23) to 23.42, marking an increase of 4.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has decreased from 3.45 (Mar 23) to 3.15, marking a decrease of 0.30.
- For Price / BV (X), as of Mar 24, the value is 5.14. This value exceeds the healthy maximum of 3. It has decreased from 7.07 (Mar 23) to 5.14, marking a decrease of 1.93.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has decreased from 3.45 (Mar 23) to 3.15, marking a decrease of 0.30.
- For EarningsYield, as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 23) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
- Net Profit Margin: -2.35%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.66% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -3.65% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.54
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.09
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 96.5 (Industry average Stock P/E: 42.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.84
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.35%
About the Company - Qualitative Analysis
No data availabale for About the Company
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Industry not found | Address not found | Contact not found |
Management Data not Available
FAQ
What is the latest intrinsic value of Lyka Labs Ltd?
The latest intrinsic value of Lyka Labs Ltd as on 10 March 2025 is ₹110.59, which is 0.37% lower than the current market price of 111.00, indicating the stock is overvalued by 0.37%. The intrinsic value of Lyka Labs Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹396 Cr. and recorded a high/low of ₹177/97.5 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹63 Cr and total liabilities of ₹168 Cr.
What is the Market Cap of Lyka Labs Ltd?
The Market Cap of Lyka Labs Ltd is 396 Cr..
What is the current Stock Price of Lyka Labs Ltd as on 10 March 2025?
The current stock price of Lyka Labs Ltd as on 10 March 2025 is ₹111.
What is the High / Low of Lyka Labs Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Lyka Labs Ltd stocks is ₹177/97.5.
What is the Stock P/E of Lyka Labs Ltd?
The Stock P/E of Lyka Labs Ltd is 96.5.
What is the Book Value of Lyka Labs Ltd?
The Book Value of Lyka Labs Ltd is 27.7.
What is the Dividend Yield of Lyka Labs Ltd?
The Dividend Yield of Lyka Labs Ltd is 0.00 %.
What is the ROCE of Lyka Labs Ltd?
The ROCE of Lyka Labs Ltd is 3.53 %.
What is the ROE of Lyka Labs Ltd?
The ROE of Lyka Labs Ltd is 5.07 %.
What is the Face Value of Lyka Labs Ltd?
The Face Value of Lyka Labs Ltd is 10.0.